Shopping Cart
- Remove All
- Your shopping cart is currently empty
Remdesivir (GS-5734) is a nucleoside analog, a broad-spectrum antiviral compound that exerts its activity by inhibiting the RNA-dependent RNA polymerase of viruses. Remdesivir is active against Ebola, SARS, and MERS viruses, and is potentially therapeutic against COVID-19.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $122 | In Stock | |
5 mg | $339 | In Stock | |
10 mg | $537 | In Stock | |
25 mg | $797 | In Stock | |
50 mg | $1,120 | In Stock | |
100 mg | $1,510 | In Stock | |
200 mg | $1,990 | In Stock | |
1 mL x 10 mM (in DMSO) | $450 | In Stock |
Description | Remdesivir (GS-5734) is a nucleoside analog, a broad-spectrum antiviral compound that exerts its activity by inhibiting the RNA-dependent RNA polymerase of viruses. Remdesivir is active against Ebola, SARS, and MERS viruses, and is potentially therapeutic against COVID-19. |
Targets&IC50 | MERS-CoV:74 nM (EC50), SARS-CoV:74 nM (EC50) |
In vitro | METHODS: Mouse hepatitis virus (MHV)-infected DBT cells were incubated with Remdesivir (0.01-1 µM) for 24 h, and the supernatant was analyzed for viral titer by plaque assay. RESULTS: Remdesivir effectively inhibited MHV with an EC50 of 0.03 µM. [1] METHODS: 2019-nCoV-infected Vero E6 cells were treated with Remdesivir (0-400 µM) for 48 h. Viral yield in cell supernatants was detected using qRT-PCR. RESULTS: Remdesivir effectively blocked viral infection at low micromolar concentrations and showed high SI (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87). [2] |
In vivo | METHODS: To assay antiviral activity in vivo, Remdesivir (25 mg/kg, 12% sulfobutylether-β-cyclodextrin sodium salt in water (with HCl/NaOH) at pH 5.0) was injected subcutaneously into MERS-CoV-infected Ces1c-/- hDPP4 mice twice daily. RESULTS: Prophylactic Remdesivir reduced MERS-CoV replication and disease. [3] METHODS: To assay antiviral activity in vivo, Remdesivir (25 mg/kg once daily, administered three times) and Loratadine (10 mg/kg once daily, administered four times) were administered intraperitoneally to 501Y.V2 SARS-CoV-2 infected BALB/c mice. RESULTS: The combination of Remdesivir and the antihistamine Loratadine reduced SARS-CoV-2 replication and inflammation and protected against lung injury. [4] |
Alias | GS-5734 |
Molecular Weight | 602.58 |
Formula | C27H35N6O8P |
Cas No. | 1809249-37-3 |
Smiles | C(#N)[C@]1(O[C@H](COP(OC2=CC=CC=C2)(N[C@H](C(OCC(CC)CC)=O)C)=O)[C@@H](O)[C@H]1O)C=3N4C(=CC3)C(N)=NC=N4 |
Relative Density. | 1.47 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (82.98 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 12.5 mg/mL (20.74 mM), suspension.In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.